Posted in Regulatory MSD secures EC clearance for Keytruda combination therapy for ovarian cancer April 6, 2026 Pharmaceutical Technology MSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer. RegulatoryOncologyRead full story